{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:30Z","timestamp":1787162730157,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["111-TMU303"],"award-info":[{"award-number":["111-TMU303"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2314-B016-015"],"award-info":[{"award-number":["NSTC112-2314-B016-015"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejps.2026.107435","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T07:05:13Z","timestamp":1768115113000},"page":"107435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting the DKK1\/CSF1 signaling axis to reprogram M2 macrophages and reverse chemoresistance in head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"218","author":[{"given":"Chin-Sheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang Huong","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Suan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shou","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107435_bib0020","series-title":"Computer Aided Chemical Engineering","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/B978-0-443-15274-0.50428-5","article-title":"Machine learning models for predicting membranolytic anticancer peptides","volume":"52","author":"Alimirzaei","year":"2023"},{"key":"10.1016\/j.ejps.2026.107435_bib0036","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.nano.2018.05.016","article-title":"Multifunctional core-shell nanoplatforms (gold@graphene oxide) with mediated nir thermal therapy to promote mirna delivery","volume":"14","author":"Assali","year":"2018","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejps.2026.107435_bib0011","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule csf-1r inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Devel Ther"},{"key":"10.1016\/j.ejps.2026.107435_bib0019","first-page":"22","article-title":"Macrophage polarization states in the tumor microenvironment","author":"Boutilier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2026.107435_bib0018","first-page":"13","article-title":"The role of macrophages in cancer development and therapy","author":"Cendrowicz","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107435_bib0032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107435_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.761379","article-title":"The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma","volume":"11","author":"Cheng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2026.107435_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658097","article-title":"Dickkopf-1: a promising target for cancer immunotherapy","volume":"12","author":"Chu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2026.107435_bib0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20150950","article-title":"Dickkopf-related protein 1 (dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer","volume":"213","author":"D'Amico","year":"2016","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.ejps.2026.107435_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2025.100038","article-title":"Nanomedicines targeting myeloid cells for breast cancer therapy","volume":"2","author":"Deng","year":"2025","journal-title":"Precis. Med. Eng."},{"key":"10.1016\/j.ejps.2026.107435_bib0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jlb.58.1.99","article-title":"The potential role of the macrophage colony-stimulating factor, csf-1, in inflammatory responses: characterization of macrophage cytokine gene expression","volume":"58","author":"Evans","year":"1995","journal-title":"J. Leukoc. Biol"},{"key":"10.1016\/j.ejps.2026.107435_bib0016","first-page":"15","article-title":"Cancer bioenergetics and tumor microenvironments-enhancing chemotherapeutics and targeting resistant niches through nanosystems","author":"Farhana","year":"2023","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107435_bib0021","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"Csf1\/csf1r signaling inhibitor pexidartinib (plx3397) reprograms tumor-associated macrophages and stimulates t-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.ejps.2026.107435_bib0003","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5732\/cjc.011.10267","article-title":"Metabolic alterations in cancer cells and therapeutic implications","volume":"30","author":"Hammoudi","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ejps.2026.107435_bib0031","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","article-title":"The role of tumor-associated macrophages in tumor immune evasion","volume":"150","author":"Huang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"10.1016\/j.ejps.2026.107435_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166487","article-title":"Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy","volume":"14","author":"Khan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2026.107435_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"Gm-csf: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2026.107435_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204831","article-title":"Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy","volume":"Vol. 25","author":"Li","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.ejps.2026.107435_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107435_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2026.107435_bib0002","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejps.2026.107435_bib0017","first-page":"13","article-title":"The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities","author":"Neophytou","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107435_bib0006","first-page":"13","article-title":"Targeting tumor-associated macrophages in cancer immunotherapy","author":"Petty","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107435_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41392-020-00313-5","article-title":"Emerging role of tumor cell plasticity in modifying therapeutic response","volume":"5","author":"Qin","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107435_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10608","article-title":"Cisplatin for cancer therapy and overcoming chemoresistance","volume":"8","author":"Ranasinghe","year":"2022","journal-title":"Heliyon."},{"key":"10.1016\/j.ejps.2026.107435_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like dtp state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2026.107435_bib0034","first-page":"10","article-title":"Sustained inhibition of csf1r signaling augments antitumor immunity through inhibiting tumor-associated macrophages","author":"Sato","year":"2025","journal-title":"JCI. Insight."},{"key":"10.1016\/j.ejps.2026.107435_bib0037","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/cas.70176","article-title":"Head and neck cancer immunotherapy: overcoming limitations and enhancing efficacy","volume":"116","author":"Shibata","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejps.2026.107435_bib0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2026.107435_bib0029","doi-asserted-by":"crossref","first-page":"552","DOI":"10.21037\/atm-20-3263","article-title":"Analyzing the prognostic value of dkk1 expression in human cancers based on bioinformatics","volume":"8","author":"Wei","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejps.2026.107435_bib0013","article-title":"Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment","volume":"9","author":"Wu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejps.2026.107435_bib0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107435_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106566","article-title":"Targeting csf-1r represents an effective strategy in modulating inflammatory diseases","volume":"187","author":"Xiang","year":"2023","journal-title":"Pharmacol, Res"},{"key":"10.1016\/j.ejps.2026.107435_bib0024","first-page":"60","article-title":"Role of macrophages in tumor progression and therapy (review)","author":"Xu","year":"2022","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.ejps.2026.107435_bib0038","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107435_bib0007","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (tams) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejps.2026.107435_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1248421","article-title":"Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms","volume":"11","author":"Zheng","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejps.2026.107435_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell Death. Discov."},{"key":"10.1016\/j.ejps.2026.107435_bib0035","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"Csf1\/csf1r blockade reprograms tumor-infiltrating macrophages and improves response to t-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2026.107435_bib0022","first-page":"10","article-title":"Silence of a dependence receptor csf1r in colorectal cancer cells activates tumor-associated macrophages","author":"Zhu","year":"2022","journal-title":"J. ImmunOther Cancer"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:51:20Z","timestamp":1772491880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"alternative-id":["S0928098726000096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107435","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the DKK1\/CSF1 signaling axis to reprogram M2 macrophages and reverse chemoresistance in head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107435"}}